12:00 AM
Sep 29, 2008
 |  BC Week In Review  |  Company News  |  Deals

MorphoSys, Novartis deal

MorphoSys exercised its first option to participate in development of an antibody under its 2007 deal with Novartis. The antibody's target and intended indication are undisclosed. Novartis...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >